Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Nuvei Corp
T.NVEI
Nuvei Corporation is a Canadian fintech company accelerating the business of clients around the world. Its modular, flexible and scalable technology allows companies to accept payments, offer all payout options and benefit from card issuing, banking, risk and fraud management services. Connecting businesses to their customers in over 200 markets, with local acquiring in 50 markets, 150 currencies and 716 alternative payment methods (APMs), it provides the technology and insights for customers and partners to succeed locally and globally with one integration. Its technology platform is purpose-built for eCommerce, integrated payments and business to business. Its platform enables customers to pay and/or accept payments worldwide regardless of their customers’ location, device or preferred payment method. Its technology includes gateway, global processing, APMs, currency management, global payouts, risk management, card issuing, open banking, data reporting, and reconciliation tools.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
TSX:NVEI - Post by User
Nuvei Corp
> An opportunity to buy
<< Previous
Bullboard Posts
Next >>
(6)
•••
MyHugeErection
X
View Profile
View Bullboard History
Comment by
MyHugeErection
on Jan 13, 2022 5:56pm
50 Views
Post# 34314858
RE:RE:RE:RE:An opportunity to buy
RE:RE:RE:RE:An opportunity to buy
Hey Bunser, you really pissed off bluesjunkie for him to write that message to you. Waytago man. GLTY.
Comment on this Post
<< Previous
Bullboard Posts
Next >>
Canadian government to fund Electric Royalties portfolio property
Quantum eMotion leaps by 20 per cent after Becton Dickinson deal
Canada Nickel unveils second of seven resources planned by mid-2025
BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide
NervGen Pharma: Proof that NVG-291 works?
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.